Aims: To report pregnancy outcomes and complications in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria.
Methods: A service evaluation of routinely collected medical records across 49 pregnancies in 21 women.
Results: Eculizumab was used in 37 pregnancies, 31 of which (83.